CombiMatrix 10-K 17 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 09, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	CombiMatrix Corp
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		12,680,927
Entity Public Float			$23,699,000
Amendment Flag	FALSE
Entity Central Index Key	1383183
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$1,010	$12,289
Short-term investments	4,230	1,747
Accounts receivable, net of allowance for doubtful accounts of $241 and $288	2,133	1,695
Supplies	367	171
Prepaid expenses and other assets	181	128
Total current assets	7,921	16,030
Property and equipment, net	584	581
Investments in unconsolidated subsidiaries and other	127	221
Total assets	8,632	16,832
Current liabilities:
Accounts payable, accrued expenses and other	1,107	1,367
Current portion, long-term debt	172	168
Common stock warrants		568
Total current liabilities	1,279	2,103
Capital lease obligations, net of current portion	82	65
Secured promissory note payable, net of current portion	151
Total liabilities	1,512	2,168
Stockholders' equity:
Convertible preferred stock; $0.001 par value; 5 million shares authorized; Series D - 12,000 shares authorized; none and 2,200.7 issued and outstanding	0	0
Common stock; $0.001 par value; 25 million shares authorized; 11,063,246 and 9,870,838 shares issued and outstanding	11	10
Additional paid-in capital	96,259	95,098
Accumulated other comprehensive loss	-3	-4
Accumulated net loss	-89,147	-80,440
Total stockholders' equity	7,120	14,664
Total liabilities and stockholders' equity	$8,632	$16,832

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts (in Dollars)	$241	$288
Convertible preferred stock, par value (in Dollars per share)	$0.00	$0.00
Preferred stock; shares authorized	5,000,000	5,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	11,063,246	9,870,838
Common stock, shares outstanding	11,063,246	9,870,838
Series D Convertible Preferred Stock [Member]
Preferred stock; shares authorized	12,000,000,000	12,000,000,000
Convertible preferred stock, shares issued	0	2,201
Convertible preferred stock, shares outstanding	0	2,201

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Royalties	$149,000	$163,000
Total revenues	8,042,000	6,367,000
Operating expenses:
Cost of services	4,432,000	3,527,000
Research and development	725,000	1,011,000
Sales and marketing	4,349,000	2,764,000
General and administrative	7,176,000	5,206,000
Patent amortization and royalties	114,000	254,000
Total operating expenses	16,796,000	12,762,000
Operating loss	-8,754,000	-6,395,000
Other income (expenses):
Interest income	23,000	5,000
Interest expense	-84,000	-356,000
Warrant derivative gains	152,000	2,804,000
Warrant modification charge	-44,000
Total other income (expense	47,000	2,453,000
Net loss	-8,707,000	-3,942,000
Net loss attributable to common stockholders	-8,707,000	-12,213,000
Basic and diluted net loss per share (in Dollars per share)	($0.79)	($1)
Basic and diluted net loss per share attributable to common stockholders (in Dollars per share)	($0.79)	($3.11)
Basic and diluted weighted average common shares outstanding (in Shares)	11,029,577	3,940,965
Series A Convertible Preferred Stock [Member] | Dividend Declared [Member]
Other income (expenses):
Convertible preferred stock dividends		-247,000
Convertible preferred stock dividends per share (in Dollars per share)		($0.06)
Series C Convertible Preferred Stock [Member] | Dividend Declared [Member]
Other income (expenses):
Convertible preferred stock dividends		-27,000
Convertible preferred stock dividends per share (in Dollars per share)		($0.01)
Series C Convertible Preferred Stock [Member] | Deemed Dividend From Issuing Stock [Member]
Other income (expenses):
Convertible preferred stock dividends		-1,213,000
Convertible preferred stock dividends per share (in Dollars per share)		($0.31)
Series B Convertible Preferred Stock [Member] | Deemed Dividend From Issuing Stock [Member]
Other income (expenses):
Convertible preferred stock dividends		-417,000
Convertible preferred stock dividends per share (in Dollars per share)		($0.11)
Series D Convertible Preferred Stock [Member] | Deemed Dividend From Issuing Stock [Member]
Other income (expenses):
Convertible preferred stock dividends		-6,367,000
Convertible preferred stock dividends per share (in Dollars per share)		($1.62)
Diagnostics Services [Member]
Revenues:
Diagnostic services	$7,893,000	$6,204,000

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Net loss	($8,707)	($3,942)
Unrealized loss on available-for-sale securities	1	-4
Total comprehensive loss	($8,706)	($3,946)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Convertible Preferred Stock [Member]	Series A Warrants [Member]	Series A Warrants [Member]	Series A Warrants [Member]	Series A Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Total
	USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	USD ($)	USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	USD ($)	USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	USD ($)	USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	USD ($)	USD ($)		USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
		USD ($)	USD ($)				USD ($)	USD ($)			USD ($)	USD ($)	USD ($)			USD ($)	USD ($)	USD ($)			USD ($)	USD ($)		USD ($)	USD ($)
Balance at Dec. 31, 2012																											$394,000
Balance (in Shares) at Dec. 31, 2012																											1,644.45
Issuance of convertible preferred stock, net of issuance costs (in Shares)																			12,000
Balance at Dec. 20, 2013
Balance at Dec. 31, 2012																											394,000		2,000	67,106,000		-68,227,000	-1,119,000
Balance (in Shares) at Dec. 31, 2012																											1,644.45		1,511,133
Conversion of convertible preferred stock to common stock	-394,000	1,000	393,000	394,000							1,000	-1,000				5,000	-5,000
Conversion of convertible preferred stock to common stock (in Shares)	-1,644.45	822,421			-1,610.40	535,392				-2,400	839,864				-9,799.30	4,756,946
Dividends paid in common stock																					49,000	-27,000	22,000							247,000		-247,000
Dividends paid in common stock (in Shares)																				15,141									50,307
Exercise of Series A common stock warrants																								1,000	3,141,000	3,142,000
Exercise of Series A common stock warrants (in Shares)																								1,209,634
Reclassification of derivative warrant liability from warrant exercises																														1,111,000			1,111,000
Non-cash stock compensation																														432,000			432,000
Unrealized loss on available-for-sale securities																															-4,000		-4,000
Net loss																																-3,942,000	-3,942,000
Issuance of convertible preferred stock, net of issuance costs							1,769,000		1,769,000			2,139,000		2,139,000			10,720,000		10,720,000
Issuance of convertible preferred stock, net of issuance costs (in Shares)					1,610.40	130,000				2,400					12,000
Beneficial conversion feature on convertible stock					-417,000		417,000			-1,213,000		1,213,000			-6,367,000		6,367,000
Deemed dividends from issuing convertible preferred stock				-246,000	417,000			-417,000		1,213,000			-1,213,000		6,367,000			-6,367,000
Balance at Dec. 31, 2013																													10,000	95,098,000	-4,000	-80,440,000	14,664,000
Balance (in Shares) at Dec. 31, 2013																												2,200.70	9,870,838
Conversion of convertible preferred stock to common stock																1,000	-1,000
Conversion of convertible preferred stock to common stock (in Shares)															-2,200.70	1,068,297
Exercise of Series A common stock warrants																									256,000	256,000
Exercise of Series A common stock warrants (in Shares)																								124,111
Issuance costs from various securities filings																														-82,000			-82,000
Reclassification of derivative warrant liability from warrant exercises																														416,000			416,000
Warrant modificaiton charge																														44,000			44,000
Non-cash stock compensation																														528,000			528,000
Unrealized loss on available-for-sale securities																															1,000		1,000
Net loss																																-8,707,000	-8,707,000
Balance at Dec. 31, 2014																													$11,000	$96,259,000	($3,000)	($89,147,000)	$7,120,000
Balance (in Shares) at Dec. 31, 2014																													11,063,246

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Net loss	($8,707,000)	($3,942,000)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	317,000	698,000
Non-cash stock compensation	528,000	432,000
Warrant derivative gains	-152,000	-2,804,000
Warrant modification charge	44,000
Provision for bad debts	303,000	290,000
Loss on disposal of fixed assets		49,000
Accounts receivable	-662,000	-723,000
Supplies, prepaid expenses and other assets	-169,000	294,000
Accounts payable, accrued expenses and other	-142,000	101,000
Net cash flows from operating activities	-8,640,000	-5,605,000
Investing activities:
Purchase of property and equipment, net of cash received from disposals	-210,000	-304,000
Purchase of available-for-sale investments	-6,811,000	-1,750,000
Sale of available-for-sale investments	4,250,000
Net cash flows from investing activities	-2,771,000	-2,054,000
Financing activities:
Proceeds from secured promissory note payable, net of issuance costs	328,000
Payments of secured promissory note	-69,000
Payments of capital lease obligations	-179,000	-259,000
Issuance costs relating to Series A convertible preferred stock		-106,000
Net proceeds from exercise of common stock warrants	256,000	3,142,000
Net cash flows from financing activities	132,000	17,577,000
(Decrease) increase in cash and cash equivalents	-11,279,000	9,918,000
Cash and cash equivalents, beginning	12,289,000	2,372,000
Unrealized loss on cash equivalents		-1,000
Cash and cash equivalents, ending	1,010,000	12,289,000
Cash paid in interest expense	50,000	54,000
Non-cash investing and financing activities:
Property and equipment purchased on capital leases	88,000	13,000
Make-whole Series A convertible preferred stock paid in common stock		247,000
Deemed dividends from issuing convertible preferred stock		7,997,000
Reclassification of derivative warrant liability to equity from warrant exercises and modifications	416,000	1,111,000
Series B Convertible Preferred Stock and Common Stock [Member]
Financing activities:
Net proceeds from issuance of stock		1,769,000
Series C Convertible Preferred Stock [Member]
Financing activities:
Net proceeds from issuance of stock		2,139,000
Series D Convertible Preferred Stock [Member]
Financing activities:
Net proceeds from issuance of stock	($204,000)	$10,892,000

Note_1_Description_of_Business

Note 1 - Description of Business	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1.     DESCRIPTION OF BUSINESS
	CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with, and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”), and in August 2007, we split-off from Acacia and became publicly traded on The Nasdaq Stock Market. As a result of the split-off, we ceased to be a subsidiary of, or affiliated with, Acacia.
	Description of the Company
	We provide valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care. We specialize in miscarriage analysis, prenatal and pediatric healthcare, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. We perform genetic testing utilizing a variety of advanced cytogenomic techniques, including microarray, standardized and customized fluorescent in-situ hybridization (“FISH”) and high resolution karyotyping. We emphasize support for healthcare professionals, to ensure data understanding and communication of results to patients. We deliver high-technology driven answers, with a high degree of assistance for the ordering physician and staff. Our laboratory facilities and corporate headquarters are located in Irvine, California.
	We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.
	Liquidity and Risks
	We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop new and improve existing commercial diagnostic testing services and related technologies. As of December 31, 2014, we had cash, cash equivalents and short-term investments of $5.2 million and anticipate that our cash and cash equivalent balances, combined with approximately $4.7 million of net proceeds from the sale of equity securities subsequent to year-end (see Note 13), will be sufficient to meet our cash requirements into the second quarter of 2016. In order for us to continue as a going concern beyond the second quarter of 2016 and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities will also cause dilution to our stockholders. At present, we cannot issue additional equity or convertible debt securities unless our stockholders approve amending our certificate of incorporation to increase our authorized capital stock. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including research projects and personnel, which could jeopardize our future strategic initiatives and business plans.
	Our business operations are also subject to certain risks and uncertainties, including:
		●	market acceptance of products and services;
		●	technological advances that may make our technologies and services obsolete or less competitive;
		●	increases in operating costs, including costs for supplies, personnel and equipment;
		●	variability in third-party reimbursement of our diagnostic tests;
		●	the availability and cost of capital; and
		●	governmental regulation that may restrict our business.
	Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned technologies or services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Accounting Principles and Fiscal Year End. The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”). We have a December 31 year-end.
	Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
	Basis of Presentation and Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the years ended December 31, 2014 and 2013, net positive revenue adjustments were $381,000 and $607,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable.
	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheets. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, no permanent impairment charges have been realized or recorded.
	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	●     Level 1:     Observable market inputs such as quoted prices in active markets;
	●     Level 2:     Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, such as quoted prices for similar assets or liabilities; and
	●     Level 3:     Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from one commercial insurance carrier of $318,000 exceeded 10% of our total accounts receivable balance as of December 31, 2014.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
	Accounts Receivable and Allowance for Doubtful Accounts. In the case of contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. In the case of non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.
	Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.
	Supplies. Supplies inventory, which consists primarily of raw materials to be used in the production of the arrays we use for our tests, is stated at the lower of cost or market using the first-in, first-out method.
	Property and Equipment. Property and equipment is recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Disposals are removed at cost less accumulated depreciation or amortization and any gain or loss from disposition is reflected in the consolidated statements of operations in the period of disposition. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Laboratory equipment (in years)		3 to 5
	Furniture and fixtures (in years)		5 to 7
	Computer hardware and software (in years)		3
	Leasehold improvements		Lesser of lease term or useful life of improvement
	Certain leasehold improvements, furniture and equipment held under capital leases are classified as property and equipment and are amortized over their useful lives using the straight-line method. Lease amortization is included in depreciation expense.
	Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock on Nasdaq on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.
	The weighted average assumptions used to estimate the fair value of stock option awards granted for the periods presented are noted in the table below. Expected volatility is based on the separate historical volatility of the market prices of our common stock. The risk-free rate for the expected term, using the simplified method, of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
		For the Years Ended
		December 31,
		2014			2013
	Risk free interest rate		2.3	%		1.7	%
	Volatility		107.7	%		106	%
	Expected term (in years)	6.3			6.3
	Expected dividends		0	%		0	%
	Stock-based compensation expense for 2014 and 2013 attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented was as follows (in thousands):
		For the Years Ended
		December 31,
		2014			2013
	Cost of services	$	17		$	7
	Sales and marketing		67			14
	General and administrative		444			411
	Total non-cash stock compensation	$	528		$	432
	Research and Development Expenses. Prior to launching a new test or modifying an existing test, extensive laboratory validations consistent with the various regulations that govern our industry must be performed.  As a result, research and development expenses include labor, laboratory supplies, and other development costs required to maintain and improve our existing suite of diagnostic test offerings as well as to investigate and develop new tests.  Costs to acquire technologies which are utilized in research and development and which have no alternative future use are expensed when incurred. Software developed for use in our services is expensed as incurred until both (i) technological feasibility for the software has been established and (ii) all research and development activities for the other components of the system have been completed. We believe these criteria are met after we have received evaluations from third-party test sites and completed any resulting modifications to the services. Expenditures to date have been classified as research and development expense.
	Advertising. Costs associated with marketing and advertising of our services are expensed as incurred. For the years ended December 31, 2014 and 2013, we incurred marketing and advertising expenses of $376,000 and $249,000, respectively.
	Income Taxes. We recognize income taxes on an accrual basis based on tax positions taken or expected to be taken in our tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however.
	Other Comprehensive Loss. Components of comprehensive loss include unrealized gains and losses on available-for-sale securities and are included in the consolidated statements of comprehensive loss.
	Segments. We have determined that we operate in one segment for financial reporting purposes.
	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase CombiMatrix stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
		For the Years Ended
		December 31,
		2014			2013
	Common stock options		690,904			639,019
	Restricted stock units		302,725			-
	Common stock warrants		7,408,905			7,623,677
	Series D preferred stock convertible into common stock.		-			1,068,297
	Excluded potentially dilutive securities		8,402,534			9,330,993
	Recent Accounting Pronouncements. In November 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance on determining whether a host contract in a hybrid financial instrument issued in the form of a share is more akin to debt or to equity. This guidance does not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required, but instead clarifies how current GAAP should be interpreted in the evaluation of the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share, thereby reducing existing diversity in practice. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within that fiscal year. We do not expect the adoption of this guidance to have a material effect on our consolidated financial statements.
	In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from generally accepted accounting principles. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new guidance becomes effective and will be adopted in the first quarter of fiscal year 2017 with early adoption not permitted. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.
	In April 2014, the FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. The changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. We do not believe adoption of this guidance will have a material impact on our consolidated financial statements or related disclosures.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. Under this guidance, an unrecognized tax benefit, or a portion of an unrecognized tax benefit that exists at the reporting date, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if certain criteria are met. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2013 with early adoption permitted. The adoption of this guidance did not have a material impact on our consolidated financial statements or related disclosures.
	In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income or loss on the respective line items in net income or loss. The new accounting guidance does not change the items that must be reported in other comprehensive income or loss or when an item of other comprehensive income or loss must be reclassified to net income or loss. The guidance is effective prospectively for fiscal years beginning after December 15, 2012 and we were required to adopt these new provisions during the first quarter of 2013. As the guidance requires additional presentation only, there was no impact to our consolidated results of operations or financial position.

Note_3_Cash_and_Shortterm_Inve

Note 3 - Cash and Short-term Investments	12 Months Ended
	Dec. 31, 2014
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents Disclosure [Text Block]	3.      CASH AND SHORT-TERM INVESTMENTS
	As of December 31, 2014 and 2013, we held $1.0 million and $12.3 million in cash and cash equivalents and $4.2 million and $1.7 million of short-term investments, respectively, which are reported at fair value. Cash, cash equivalents and short-term investments consisted of the following as of December 31, 2014 and 2013 (in thousands):
		As of December 31, 2014									As of December 31, 2013
				Unrealized					Fair				Unrealized					Fair
		Cost		Gain		Loss			Value		Cost		Gain		Loss			Value
	Cash and money market securities	$	1,010	$	-	$	-		$	1,010	$	11,290	$	-	$	-		$	11,290
	Corporate bonds		1,003		-		-			1,003		-		-		-			-
	Certificates of deposit		3,230		-		(3	)		3,227		2,750		-		(4	)		2,746
		$	5,243	$	-	$	(3	)	$	5,240	$	14,040	$	-	$	(4	)	$	14,036
	Included in cash and cash equivalents.	$	1,010	$	-	$	-		$	1,010	$	12,290	$	-	$	(1	)	$	12,289
	Included in short-term investments		4,233		-		(3	)		4,230		1,750		-		(3	)		1,747
		$	5,243	$	-	$	(3	)	$	5,240	$	14,040	$	-	$	(4	)	$	14,036
	There were no realized gains or losses for the years ended December 31, 2014 and 2013.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4.     FAIR VALUE MEASUREMENTS
	The following table summarizes, for each major category of financial assets or liabilities measured on a recurring basis, the respective fair value at December 31, 2014 and 2013, and the classification by level of input within the fair value hierarchy defined above (in thousands):
					Fair Value Measurements
	31-Dec-14	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	676		$	676	$	-	$	-
	Short-term investments		4,230			-		4,230		-
	Total	$	4,906		$	676	$	4,230	$	-
					Fair Value Measurements
	31-Dec-13	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	8,263		$	7,264	$	999	$	-
	Short-term investments		1,747			-		1,747		-
	Total	$	10,010		$	7,264	$	2,746	$	-
	Liabilities:
	Derivative warrant liability	$	568		$	-	$	-	$	568
	The following table is a reconciliation of financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the year ended December 31, 2014 (in thousands):
		Derivative
		Warrant
		Liability
	Balance, December 31, 2013	$	568
	Changes in fair value		(152	)
	Reclassifications		(416	)
	Balance, December 31, 2014	$	-
	The fair value of the derivative warrant liability is based on Level 3 inputs. For this liability, we developed our own assumptions that do not have observable inputs or available market data to support the fair value recorded. See Note 11 for further discussion of the derivative warrant liability.

Note_5_Property_and_Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5.     PROPERTY AND EQUIPMENT
	Property and equipment consists of the following (in thousands):
		December 31,
		2014			2013
	Laboratory equipment	$	1,599		$	1,737
	Furniture and fixtures		290			225
	Computer hardware and software		38			42
	Leasehold improvements		252			279
			2,179			2,283
	Less - accumulated depreciation and amortization		(1,595	)		(1,702	)
		$	584		$	581
	Depreciation and amortization expense was $312,000 and $352,000 for the years ended December 31, 2014 and 2013, respectfully. The net book value of assets under capital lease obligations was $159,000 and $246,000 as of December 31, 2014 and 2013, respectively.

Note_6_Balance_Sheet_Component

Note 6 - Balance Sheet Components	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	6.     BALANCE SHEET COMPONENTS
	Accounts payable, accrued expenses and other accrued expenses consist of the following (in thousands):
		December 31,
		2014		2013
	Accounts payable	$	381	$	636
	Payroll and other employee benefits		149		353
	Accrued vacation		207		144
	Royalties		252		211
	Other accrued expenses		118		23
		$	1,107	$	1,367

Note_7_Income_Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	7.     INCOME TAXES
	The tax effects of temporary differences and carryforwards that give rise to significant portions of deferred assets and liabilities consist of the following (in thousands):
		December 31,
		2014			2013
	Deferred tax assets:
	Deferred settlement costs	$	797		$	1,215
	Stock-based compensation		466			423
	Accrued liabilities and other		442			500
	Net operating loss carryforwards and credits		64,804			61,756
	Total deferred tax assets		66,509			63,894
	Less: valuation allowance		(66,514	)		(63,944	)
	Deferred tax assets, net of valuation allowance		(5	)		(50	)
	Deferred tax liabilities:
	Depreciation and amortization		5			50
	Net deferred tax liability	$	-		$	-
	A reconciliation of the federal statutory income tax rate and the effective income tax rate is as follows:
		December 31,
		2014			2013
	Statutory federal tax rate		(34%	)		(34%	)
	Impact on state tax rates		1	%		(7%	)
	Warrant valuation		(1%	)		(22%	)
	Cancellation of vested non-qualified stock options		0	%		1	%
	Valuation allowance		29	%		59	%
	Other non deductible permanent items		5	%		3	%
			0	%		0	%
	At December 31, 2014 and 2013, we had net deferred tax assets totaling approximately $66.5 million and $63.9 million, respectively. These assets are offset by valuation allowances due to our determination that the criteria for asset recognition have not been met, as well as by deferred tax liabilities. At December 31, 2014, we had federal net operating loss carryforwards of approximately $169 million, which begin to expire in 2017 through 2033. In addition, we have tax credit carryforwards of approximately $5.2 million. Utilization of net operating loss carryforwards and tax credit carryforwards are subject to the “change of ownership” provisions under Section 382 of the Internal Revenue Code. The amount of such limitations has not been determined. Also, given that our net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which we operate. We have no unrecognized tax benefits as of December 31, 2014 and 2013.

Note_8_Secured_Promissory_Note

Note 8 - Secured Promissory Note	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8.     SECURED PROMISSORY NOTE
	On May 20, 2014 (“Execution Date”), we executed a secured promissory note (the “Note”) with ACC Investment Ltd. in the amount of $350,000, payable in equal amortized payments over a thirty-six month period (the “Term”) from the Execution Date. The Note bears an annual interest rate of 10% and is secured by certain laboratory equipment used in our microarray services business. Legal and other closing costs totaling $22,000 were capitalized with the Note and are being amortized over the Term as interest expense. As of December 31, 2014, the fair value of the Note approximated its carrying value of $281,000, which is exclusive of unamortized closing costs of $18,000. The current portion of the $263,000 in net carrying value of the Note was $112,000.

Note_9_Commitments_and_Conting

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9.     COMMITMENTS AND CONTINGENCIES
	Leases
	On October 24, 2014, we entered into an Amendment No. 6 to the Lease (the “Amendment”) with PPC Goddard Investment, LLC (the “Landlord”), concerning our existing building lease for laboratory space and corporate offices in Irvine, California. The Amendment, in part (i) extends the term of the Lease by five years until January 31, 2020; (ii) provides for monthly base rent (excluding allocated common area expenses) of $1.00 per square foot per month for the first year, increasing by $0.05 per year thereafter throughout the term of the lease to a maximum of $1.20 per square foot per month in the fifth year of the lease; (iii) provides for certain tenant improvements to be provided by the Landlord at no cost to us; (iv) at our choosing, provides for an early termination after thirty-six months upon payment by us of the Landlord’s unamortized tenant improvement cost and unamortized brokerage commissions payable in connection with the Amendment at an interest rate of eight percent; and (v) provides for a period of abated rent for the first three months of the renewal period (or February 1, 2015 through April 30, 2015). Pursuant to the Amendment, the monthly base rent together with the current estimated monthly common area expense of $0.85 per square foot will result in an aggregate monthly expense of approximately $22,500 for the first year, assuming no increase in the monthly common area expense, and increasing to approximately $25,000 per month for the fifth year, assuming we do not exercise our option to terminate the lease after thirty-six months, and assuming no increase in the monthly common area expense.
	At December 31, 2014, we had eleven capital leases for laboratory equipment with original purchase amounts totaling $257,000 and with useful lives of five years. As of December 31, 2014, the remaining lease obligations (including interest charges) were $158,000 with minimum future lease payments shown below. The weighted average interest rate on the capital lease obligations was 8.2%, based on remaining lease obligations as of December 31, 2014. The fair value of the capital lease obligations was not significantly different from their carrying amounts for all periods presented.
	Future minimum lease payments for all of our facilities and leased equipment are as follows (in thousands):
	Years ending December 31:
		Operating		Capital
		Leases		Leases			Total
	2015	$	111	$	69		$	180
	2016		153		51			204
	2017		160		22			182
	2018		167		11			178
	2019 and thereafter		189		5			194
	Total minimum lease payments	$	780		158		$	938
	Less- imputed interest				(17	)
	Present value of capital lease obligations				141
	Less- current portion				(59	)
	Capital lease obligations, net of current portion..			$	82
	Rent expense for the years ended December 31, 2014 and 2013 was $288,000 and $297,000, respectively.
	Executive Severance
	We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (the “Severance Plan”) that affects certain of our senior management-level employees who are classified as “Section 16 Officers” of the Company.  Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary; (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependents for a pre-determined period of time.  Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code.  The Severance Plan is administered by a plan administrator, which initially is the Compensation Committee of the Board of Directors.  In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements.
	Litigation
	On September 30, 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $100,000 in each of the years ended December 31, 2014 and 2013, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.
	On February 14, 2011, Relator Michael Strathmann (“Strathmann”) served us with a complaint (“the Complaint”) filed in the Superior Court of the State of California for the County of Orange (the “Superior Court”). The Complaint alleged we and our former parent Acacia Research Corporation submitted false and fraudulent insurance claims to National Union Fire Insurance Company under the Directors and Officers Policy issued to Acacia, in connection with a prior lawsuit that was settled with Nanogen, Inc., thereby allegedly violating the California Insurance Fraud Prevention Act, and sought penalties and unspecified treble damages. On May 4, 2011, the Superior Court dismissed the Complaint by ordering that it be stricken for violation of the California Anti-SLAPP statute, which prevents plaintiffs from filing abusive lawsuits against public policy. On June 15, 2011, Strathmann filed a Notice of Appeal with the California Court of Appeals, appealing the granting of the Motion to Strike. On October 24, 2012, the California Court of Appeals reversed the Superior Court’s dismissal, finding that the anti-SLAPP statute was not applicable and remanding the case to the Superior Court. Strathmann filed an Amended Complaint, and we and Acacia filed our Answer to that pleading. A trial was held between June and August of 2014, followed by closing briefs and arguments filed in September and October of 2014. On January 2, 2015, the Superior Court issued a tentative ruling and proposed statement of decision in favor of us, Acacia and Amit Kumar and against all claims of Strathmann. Specifically, the Superior Court determined that we had no fraudulent intent when we pursued insurance benefits under the National Union Directors and Officers Policy over a decade ago. On March 6, 2015 the Superior Court issued its final Statement of Decision, confirming its tentative ruling that Strathmann failed to prove that we (or any other defendant) had a fraudulent intent when we pursued insurance benefits from National Union.  Also on March 6, 2015 the Superior Court entered a Judgment in favor of all defendants and against Strathmann, and ordered that Strathmann’s Complaint be dismissed with prejudice.  A Notice of Entry of Judgment was filed with the Superior Court on March 11, 2015. If Strathmann chooses to appeal the Judgment, he has 60 days from March 11, 2015 to file a Notice of Appeal.  The cost of defending an appeal alone could have a material adverse effect on our financial condition and results of operations.
	From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Any legal costs resulting from claims or legal actions are expensed as incurred.

Note_10_Retirement_Savings_Pla

Note 10 - Retirement Savings Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	10.     RETIREMENT SAVINGS PLAN
	We have an employee savings and retirement plan under section 401(k) of the Internal Revenue Code (the “Retirement Plan”). The Retirement Plan is a defined contribution plan in which eligible employees may elect to have a percentage of their compensation contributed to the Retirement Plan, subject to certain guidelines issued by the Internal Revenue Service. We may contribute to the Retirement Plan at the discretion of our board of directors. There were no contributions made by us during any of the years presented.

Note_11_Stockholders_Equity

Note 11 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	11. STOCKHOLDERS’ EQUITY
	Series A Convertible Preferred Stock and Warrants Financing
	During the fourth quarter of 2012, we issued Series A convertible preferred stock (the “Series A Stock”) and warrants to purchase common stock (the “Series A Warrants”) to certain accredited investors (the “Series A Investors”) for gross proceeds of $2.5 million. During the fourth quarter of 2012 and the first quarter of 2013, all of the Series A convertible preferred stock converted into 1.25 million shares of common stock, and during 2013, 1.2 million shares of common stock were issued from the exercise of the Series A Warrants, leaving Series A Warrants to purchase 292,817 shares of common stock unexercised as of December 31, 2013. During 2014, Series A Investors exercised Series A Warrants to purchase 124,111 shares of our common stock, resulting in proceeds of $256,000 to us.
	Holders of the Series A Stock were entitled to receive accruing dividends at the annual rate of 6%, payable semi-annually. Upon conversion of Series A Stock into common stock, we paid to each holder of Series A Stock converting to common stock, as a “make-whole” payment in common stock, an amount equal to $118 per $1,000 of stated value of Series A Stock so converted, less the aggregate amount of dividends previously paid on such converting Series A Stock. Early in 2013, 50,307 shares of common stock were issued to the Series A Investors in payment of the make-whole and accrued dividends related to the Series A Stock conversions. The combination of make-whole and accrued dividends paid in shares of common stock for the year ended December 31, 2013 was $246,000.
	For as long as the Series A Warrants remain unexercised through their expiration date in October 2018, we may not sell securities at an effective price per share less than $4.91 except for certain exempt issuances, unless waivers from the Series A Investors are obtained. Prior to June 2014, the exercise price of the Series A Warrants and the number of shares of common stock underlying the Series A Warrants were subject to full-ratchet anti-dilution adjustments in the event we issue securities, other than certain excepted issuances, at a price below the then current exercise price of the Series A Warrants. In June 2014, we executed modification agreements (the “Modification”) with the remaining Series A Investors to remove the full-ratchet anti-dilution adjustment provisions as well as the Black-Scholes cash buy-back provisions from the terms of the Series A Warrants, thereby eliminating the requirement for derivative accounting and liability classification for the Series A Warrants as of the Modification date. In consideration for agreeing to these Modifications, we issued additional warrants to the Series A Investors to purchase 25,303 shares of common stock at an exercise price of $2.06 per share and an expiration date in April 2018, which are equivalent to the terms of the existing Series A Warrants as modified by the Modification, but are not subject to any registration rights.
	We account for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants must be accounted for as derivative financial instruments if the warrants contain full-ratchet anti-dilution provisions, which preclude the warrants from being considered indexed to our own stock. Prior to the Modification, the Series A Warrants issued to Series A Investors contained such provisions, thus requiring us to treat them as derivative financial instruments, to be recorded at fair value at issuance and subsequently adjusted to fair value at each reporting date, with the corresponding adjustment reflected as a non-operating credit / charge in the consolidated statement of operations. We valued the Series A Warrants using the Monte-Carlo simulation method using the following assumptions immediately prior to the Modification: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the individual Series A Warrant terms of 3.8 years; (iii) historical volatilities commensurate with the term of the Series A Warrants of 129.6%; (iv) risk-free interest rates commensurate with the term of the Series A Warrants of 1.2%; and (v) simulated anti-dilution impact assuming various probabilities that we will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise prices during the Series A Warrant terms. The result of this valuation simulation was to value the remaining Series A Warrants held by Series A Investors at $281,000 as of the Modification date. As a result, warrant derivative gains of $152,000 were recognized during the second quarter of 2014, and the remaining $281,000 was reclassified to additional paid-in capital. As a result of a similar valuation analysis performed during the first quarter ended March 31, 2014, the combined warrant derivative gains recognized in our consolidated statements of operations and the amount of warrant derivative liabilities reclassified to stockholders’ equity resulting from Series A Warrant exercises for the year ended December 31, 2014 was $152,000 and $416,000, respectively. The additional Series A Warrants to purchase 25,303 shares of common stock issued to Series A Investors as consideration for agreeing to the Modification were valued using the Black-Scholes valuation model, using the following assumptions as of the Modification: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the individual Series A Warrant terms of 3.8 years; (iii) historical volatility commensurate with the term of the Series A Warrants of 129.6%; and (iv) risk-free interest rates commensurate with the term of the Series A Warrants of 1.2%. The resulting valuation of $44,000 was recognized as a non-operating charge in our consolidated statements of operations for year ended December 31, 2014.
	During 2013, we valued the Series A Warrants using the Monte-Carlo simulation method using the following assumptions at each valuation date: (i) closing stock price and Series A Warrant contractual exercise price; (ii) term to expiration commensurate with the remaining Series A Warrant terms of 5.0 to 4.3 years; (iii) historical volatilities commensurate with the term of the remaining Series A Warrants of between 114.5% to 126.5%; (iv) risk-free interest rates commensurate with the term of the remaining Series A Warrants of 0.8% to 1.4%; and (v) simulated anti-dilution impact assuming various probabilities that we will raise additional capital by issuing equity securities at prices above or below the current contractual Series A Warrant exercise price during the Series A Warrant terms. During 2013, the warrant derivative liability decreased due primarily to lower stock prices as well as from Series A Warrant exercises, resulting in a net gain of $2.8 million and a reclassification to additional paid-in capital of $1.1 million, respectively.
	Amortization of the deferred offering-related costs allocated to the Series A Warrants was $280,000 during the year ended December 31, 2013, and was recognized as a component of interest expense. See Note 13 for further discussion of modifications made to the Series A Warrants subsequent to year-end.
	Series B Convertible Preferred Stock Financing
	On March 19, 2013, we entered into a securities purchase agreement (the “Series B Purchase Agreement”) with an existing institutional investor (the “Series B Investor”) to purchase 130,000 shares of common stock at a price of $3.05 per share and approximately 1,610.4 units consisting of, in the aggregate, Series B 6% convertible preferred stock (the “Series B Stock”) and warrants to purchase up to 275,000 shares of common stock at an exercise price of $3.49 per share (the “Series B Warrants”) in a registered direct offering (the “Series B Financing”) of securities sold off of our shelf registration statement on Form S-3. The Series B Financing closed on March 20, 2013 (the “Series B Closing”). The Series B Stock and Series B Warrants were sold in multiples of fixed combinations, with each fixed combination consisting of one share of Series B Stock and a Series B Warrant to purchase approximately 171 shares of common stock. Each fixed combination of Series B Stock and Series B Warrants was sold at a price of $1,000. The Series B Stock was initially convertible into an aggregate of 528,000 shares of common stock at an initial conversion price of $3.05 per share. During 2013, the Series B Investor converted all of the Series B Stock into common stock.
	The Series B Warrants were not exercisable for six months from the Series B Closing, and the Series B Stock accrued dividends at an annual rate of 6% beginning six months after the Series B Closing, assuming the Series B Stock had not been converted by that time. Upon the Series B Closing, we received proceeds of $1.8 million, net of placement agent fees and other related paid and accrued costs. Given that the effective conversion price of the Series B Stock was below the closing market price of our common stock at the time of the Series B Closing, we recognized a beneficial conversion feature in the amount of $417,000. Since the Series B Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings.
	The Series B Warrants have a 5½ year term as well as a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series B Warrants, and were not exercisable for the first six months following issuance. The Series B Warrants are not subject to price anti-dilution protection. We also agreed with the Series B Investor pursuant to the Series B Purchase Agreement that, except under certain permitted circumstances, until the time that less than 7.5% of the Series B Warrants remain outstanding, neither we nor our subsidiaries shall issue, or enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Series B Warrants. See Note 13 for further discussion of modifications made to the Series B Warrants subsequent to year-end.
	Series C Convertible Preferred Stock Financing
	On May 3, 2013, we entered into a securities purchase agreement (the “Series C Purchase Agreement”) with certain accredited investors (the “Series C Investors”), pursuant to which we sold and issued 1,200 shares of our newly created Series C 6% convertible preferred stock (the “Series C Stock”) to the Series C Investors at a purchase price of $1,000 per share in an initial closing that occurred on May 6, 2013 (the “Series C First Closing”) and sold and issued 1,200 additional shares of Series C Stock to the Series C Investors on June 28, 2013 at a purchase price of $1,000 per share after stockholder approval was obtained on June 27, 2013 (the “Series C Second Closing”) (combined, the “Series C Financing”). After certain offering-related costs paid, the net proceeds from the Series C Financing was approximately $2.14 million.
	As a result of the Series C Second Closing, the conversion price for the Series C Stock was set to $2.85759 per share, or the equivalent of 839,864 shares of common stock issuable upon conversion of all Series C Stock. The Series C Stock was entitled to 6% annual dividends, and accrued dividends were payable semi-annually, and also on the date of conversion of any Series C Stock, in cash or, subject to certain conditions and at our election, in shares of common stock. If the dividends were paid in shares of common stock, the number of shares of common stock comprising the dividend on each share of Series C Stock was valued at a 20% discount to the average of the daily volume weighted average price for the five-day trading period immediately prior to the dividend payment date. Given that the effective conversion price of the Series C Stock was below the closing market price of our common stock at the time of both of the Series C closings, we recognized beneficial conversion features in the amount of $1.2 million, which were limited to and reduced the net proceeds allocated to the Series C Stock. Since the Series C Stock was immediately convertible into common stock, the beneficial conversion feature was treated as a deemed dividend charged to retained earnings. During the remainder of 2013, the Series C Investors converted all 2,400 shares of Series C stock into 839,864 shares of common stock.
	In addition to the issuance of the Series C Stock, we issued warrants at the Series C First Closing to purchase 491,803 shares of our common stock with an exercise price of $3.77 per share and at the Series C Second Closing, we issued additional warrants to purchase 491,803 shares of our common stock with an exercise price of $3.55 per share (collectively, the “Series C Warrants”). The Series C Warrants have a 5½ year term, were not exercisable for the first six months following issuance and include a cash-less exercise provision which is only applicable if the common stock underlying the Series C Warrants is not subject to an effective registration statement or otherwise cannot be sold without restriction pursuant to Rule 144. Until all Series C Investors no longer hold Series C Warrants: (i) we may not sell any variable rate securities except for certain exempt issuances; and (ii) if we enter into a subsequent financing on more favorable terms than the Series C Financing, then the agreements between us and the Series C Investors will be amended to include such more favorable terms. In addition, until 7.5% or less of the Series C Warrants remain unexercised, we may not sell any dilutive securities, except for certain exempt issuances. See Note 13 for further discussion of modifications made to the Series C Warrants subsequent to year-end.
	Series D Convertible Preferred Stock Financing
	On December 20, 2013 (the “Series D Closing”), we closed an underwritten public offering (the “Series D Offering”) and issued 12,000 units of securities to investors, with each unit consisting of: (i) one share of Series D preferred stock (“Series D Stock”) convertible into shares of our common stock equal to 1,000 divided by the conversion price of $2.06, which was 72.5% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on December 16, 2013, the date we executed the underwriting agreement (“UA date”); and (ii) one warrant exercisable for 485.4369 shares of our common stock, at an exercise price per share equal to $3.12 (“Series D Warrants”), which was 110% of the consolidated closing bid price of our common stock on the Nasdaq Capital Market on the UA date. The shares of common stock underlying the Series D Stock and Series D Warrants were registered on a Registration Statement on Form S-1, which was declared effective by the SEC on December 16, 2013. The Series D Stock was immediately convertible and the Series D Warrants were immediately exercisable for shares of common stock and have a term of five years. In total, there were 5,825,243 shares of common stock issuable upon conversion of the Series D Stock and up to 5,825,243 shares of common stock issuable upon exercise of the Series D Warrants. The units were sold for a purchase price equal to $1,000 per unit, resulting in gross proceeds of $12 million at the Series D Closing. After certain offering-related costs paid to the underwriters and others at the closing and through December 31, 2014, net proceeds received by us were approximately $10.7 million. As of December 31, 2013, 9,799.3 shares of Series D Stock had converted into 4,756,946 shares of common stock. During the first quarter of 2014, all of the remaining Series D Stock converted into an additional 1,068,297 shares of common stock. Also as a result of the Series D Offering, the exercise price of the then-outstanding Series A Warrants automatically ratcheted down by their terms from their then exercise price of $2.86 per share to an adjusted exercise price of $2.06 per share, and the underlying shares exercisable was automatically increased by 81,910 shares. A registration statement on Form S-3 was filed in order to register these shares as per the terms of our original Series A offering documents.
	Warrants
	Outstanding warrants to purchase our common stock are as follows:
			Shares of Common Stock
			Issuable from Warrants
			Outstanding as of December 31,				Exercise
			2014		2013		Price			Expiration
	Liability-classified warrants:
	Oct-12			-		292,817	$	2.06	(1)	Apr-18
				-		292,817
	Equity-classified warrants:
	Dec-13			5,825,243		5,825,243	$	3.12		Dec-18
	Jun-13			491,803		491,803	$	3.55		Dec-18
	May-13			491,803		491,803	$	3.77		Nov-18
	Mar-13			275,000		275,000	$	3.49		Sep-18
	Oct-12			194,009		-	$	2.06	(1)	Apr-18
	Apr-11			131,047		131,047	$	21.4		Apr-16
	Oct-09			-		3,000	$	77.8		Oct-14
	May-09			-		2,967	$	75.00 - $90.00		May 2014 - July 2014
	May-09			-		109,997	$	90		May-14
	Total			7,408,905		7,330,860
	Total - all warrants			7,408,905		7,623,677
	-1	Prior to the anti-dilution adjustments which occurred on March 20, 2013, June 28, 2013 and December 20, 2013, these warrants had an initial exercise price of $9.50 per share. Also, due to the Modification previously discussed, these warrants are no longer liability classified as of September 30, 2014.
	As discussed in Note 13 below, in connection with the February 18, 2015 Private Placement Warrant Financing, the October 2012, March 2013, May 2013 and June 2013 warrants reflected above were modified such that the exercise prices of those warrant contracts were lowered to $1.97, and their respective expiration dates were increased by six months.

Note_12_EquityBased_Compensati

Note 12 - Equity-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	12.     EQUITY-BASED COMPENSATION
	Our employees participate in the CombiMatrix Corporation 2006 Stock Incentive Plan (the “CombiMatrix Plan”), which was approved by our board of directors in 2006. In addition, during 2005, the board of directors of our wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc., approved the CombiMatrix Molecular Diagnostics 2005 Stock Award Plan (the “CMDX Plan”). Our board of directors believes that granting employees stock-based awards from the CombiMatrix Plan is in the best interest of our Company and our stockholders. No awards have been granted to the CMDX Plan since 2010, and it is no longer being utilized.
	CombiMatrix Corporation 2006 Stock Incentive Plan
	The CombiMatrix Plan is administered by the Compensation Committee (the “Committee”) of our Board of Directors. The Committee determines which eligible individuals are to receive option grants or stock issuances under the CombiMatrix Plan, the time or times when the grants or issuances are to be made, the number of shares subject to each grant or issuance, the status of any granted option as either an incentive stock option or a non-statutory stock option under the federal tax laws, the vesting schedule to be in effect for the option grant or stock issuance and the maximum term for which any granted option is to remain outstanding.
	The CombiMatrix Plan is divided into three separate equity incentive programs: a discretionary option grant / stock appreciation right program, a stock issuance program, and an automatic option grant program for outside directors. To date, the discretionary option grant program has been the primary program used in awarding stock-based compensation. Under the discretionary option grant program, the Committee may grant non-statutory options to purchase shares of CombiMatrix stock to eligible individuals in our employ (including employees, non-employee board members and consultants) at an exercise price not less than 100% of the fair market value of those shares on the grant date, and incentive stock options to purchase shares of CombiMatrix stock to eligible employees at an exercise price not less than 100% of the fair market value of those shares on the grant date. Options are generally exercisable over a three- or four-year vesting term following the date of grant and expire ten years after the grant date. The Committee may grant other forms of equity based compensation, such as restricted stock units (“RSU’s”), which the Committee awarded to certain executives and directors of the Company for the first time during 2014. RSU awards vest in equal annual installments over a four-year period following the date of grant. At December 31, 2014, there were approximately 2.0 million authorized shares under the CombiMatrix Plan, with approximately 995,000 shares available for grant.
	The following is a summary of the stock option activities under the CombiMatrix Plan for 2014 and 2013:
							Weighted		Aggregate
					Weighted		Contractual		Intrinsic
					Average		Term		Value
		Shares			Price		(in years)		('000s)
	Balance at December 31, 2012		163,933		$	35.21		7.3	$	23
	Granted		502,586		$	3.29
	Exercised		-		$	-
	Forfeited		(13,750	)	$	9.68
	Cancelled		(13,750	)	$	28.94
	Balance at December 31, 2013		639,019		$	10.79		8.7	$	1
	Granted		158,500		$	2.87
	Exercised		-		$	-
	Forfeited		(103,555	)	$	3.89
	Cancelled		(6,105	)	$	31.09
	Balance at December 31, 2014		687,859		$	9.82		8	$	-
	Exercisable at December 31, 2013		98,259		$	47.75		6	$	-
	Exercisable at December 31, 2014		173,153		$	29.05		6.3	$	-
	Information related to options granted under the CombiMatrix Plan for 2014 and 2013 is as follows:
		December 31,
		2014			2013
	Weighted average fair values of options granted	$	2.4		$	2.39
	Options granted with exercise prices:
	Greater than market price on the grant date		-			-
	Equal to market price on the grant date		158,500			502,586
	Less than market price on the grant date		-			-
	The aggregate fair value of options vested during the years ended December 31, 2014 and 2013 was $359,000 and $279,000, respectively. As of December 31, 2014, the total unrecognized compensation expense related to non-vested stock option awards was $867,000, which is expected to be recognized over a weighted average term of approximately 2.4 years.
	The following is a summary of the RSU activities under the CombiMatrix Plan for 2014 (there was no activity in 2013):
					Weighted
		Restricted			Average
		Stock			Grant Date
		Units			Fair Value
	Nonvested RSU's at December 31, 2013		-		$	-
	Granted		380,220		$	2.83
	Vested		-		$	-
	Cancelled		(77,495	)	$	2.81
	Nonvested RSU's at December 31, 2014		302,725		$	2.83
	Vested RSU's at December 31, 2014		-		$	-
	As of December 31, 2014, the total unrecognized compensation expense related to RSU awards was $672,000, which is expected to be recognized over a weighted-average period of approximately 3.1 years.
	CombiMatrix Molecular Diagnostics 2005 Stock Award Plan
	Our wholly owned subsidiary, CMDX, executed the CMDX Plan, with plan provisions and terms similar to that of the CombiMatrix Plan as described above. At December 31, 2014, there were 4.0 million authorized shares available under the CMDX Plan, with approximately 3.7 million shares available for grant. However, our Board of Directors has no intention of utilizing this plan in the future.
	The following is a summary of stock option activities for the CMDX Plan for 2014 and 2013:
							Weighted		Aggregate
					Weighted		Contractual		Intrinsic
					Average		Term		Value
		Shares			Price		(in years)		('000s)
	Balance at December 31, 2012		291,000		$	0.34		3.1	$	51
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		-		$	-
	Balance at December 31, 2013		291,000		$	0.34		2.1	$	51
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		-		$	-
	Balance at December 31, 2014		291,000		$	0.34		1.1	$	51
	Exercisable at December 31, 2013		241,000		$	0.3		2.1	$	50
	Exercisable at December 31, 2014		241,000		$	0.3		1.1	$	50
	There were no option grants during 2014 or 2013 under the CMDX Plan. The fair value of options vested during the years ended December 31, 2014 and 2013 was not significant. As of December 31, 2014, the total unrecognized compensation expense related to non-vested stock option awards was not significant.
	Stock Option Awards Granted to Non-Employees
Stock option expense reflected in the consolidated statements of operations related to stock options issued to our non-employee scientific advisory board members and consultants are recognized at fair value using the Black-Scholes option-pricing model with weighted average assumptions as disclosed in Note 2 under “Stock-Based Compensation.” For the years ended December 31, 2014 and 2013, non-cash charges recognized from stock option awards granted to non-employees was not significant.

Note_13_Subsequent_Events

Note 13 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	13.     SUBSEQUENT EVENT
	Series E Convertible Preferred Stock Financing
	On February 13, 2015, we and certain accredited institutional pre-existing investors (the “Series E Investors”) entered into a securities purchase agreement (the “Series E Purchase Agreement”), pursuant to which sold 1,541,998 shares common stock at a price of $1.75 per share, 2,201.493 shares of Series E 6% Convertible Preferred Stock (the “Series E Preferred Stock”) and warrants to purchase 700,000 shares of common stock at an exercise price of $1.97 per share, which was the consolidated closing bid price of our common stock on Nasdaq immediately prior to entering into the Series E Purchase Agreement (the “Series E Warrants”, and the transactions contemplated by the Series E Purchase Agreement, the “Series E Financing”). The Series E Preferred Stock and Series E Warrants were sold in a fixed combination consisting of one share of Series E Preferred Stock and a Series E Warrant to purchase approximately 317.965 shares of Common Stock. Each fixed combination of Series E Preferred Stock and Series E Warrants were sold at a price of $1,000. The Series E Preferred Stock sold is convertible into 1,257,996 shares of common stock at an initial conversion price of $1.75 per share. The Series E Preferred Stock is not convertible into greater than 19.99% of our outstanding common stock unless stockholder approval is obtained. The closing under the Series E Purchase Agreement occurred on February 18, 2015 (the “Series E Closing Date”), where we received gross proceeds of $4.9 million from the Series E Investors. We expect the net proceeds to us, after closing-related costs and expenses, to be approximately $4.7 million.
	The Series E Preferred Stock is non-voting (except to the extent required by law and except for certain consent rights relating to amending the certificate of incorporation or bylaws, and the like), but ranks senior to our common stock with respect to dividends and with respect to distributions upon a deemed dissolution, liquidation or winding-up of the Company. Each share of Series E Preferred Stock carries a 6% per annum dividend that will begin accruing six months after the Series E Closing Date and will be payable only in cash. Until the volume weighted average price of our common stock on Nasdaq exceeds 200% of the conversion price of the Series E Preferred Stock for ten consecutive trading days, the Series E Preferred Stock is subject to full ratchet price based anti-dilution protection, subject to the limits imposed by General Instruction I.B.6. of Form S-3.
	The Series E Warrants issued have a 5 ½ year term and have a cashless exercise provision in the event there is no effective registration statement covering the common stock issuable upon exercise of the Series E Warrants. The Series E Warrants are not exercisable for the first six months following issuance. The Series E Warrants are not subject to price based anti-dilution protection. Subject to the beneficial ownership limitation described below, if, after the one year anniversary of the Series E Closing Date, the volume weighted average price of our common stock on Nasdaq exceeds 200% of the exercise price for ten consecutive trading days, then we have the right to, within one trading day thereafter, call for cancellation of up to 50% of the Series E Warrants for consideration equal to $0.001 per share of common stock underlying the Series E Warrants. The Company may not exercise its call rights if, among other things, there is no effective registration statement registering the shares of common stock issuable upon exercise of the Series E Warrants or the prospectus contained in the registration statement is not available for the issuance of the shares of common stock issuable upon exercise of the Series E Warrants.
	Pursuant to the terms of the Series E Purchase Agreement, while such Series E Investor holds Series E Preferred Stock and Series E Warrants, we may not enter into an agreement to effect a “Variable Rate Transaction,” which means a transaction in which the Company: (i) issues or sells any convertible securities either (A) at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations for, the shares of the common stock at any time after the initial issuance of such convertible securities, or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company; or (ii) enters into any agreement (including, without limitation, an equity line of credit) whereby we may sell securities at a future determined price. Also, except under certain permitted circumstances: (i) until the later of the date that is six months from the closing or 30 days following the date on which less than 7.5% of the Series E Preferred Stock remains outstanding, we will not issue, or enter into any agreement to issue, any shares of common stock or equivalents thereof; (ii) until the time that less than 7.5% of the Series E Warrants remain outstanding, neither the Company nor its subsidiaries will issue, or enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Series E Warrants; (iii) until the time that less than 7.5% of the Series E Preferred Stock remains outstanding, neither the Company nor its subsidiaries will issue, or enter into any agreement to issue, common stock or equivalents thereof at a price below the conversion price of the Series E Preferred Stock unless all shares of common stock underlying the Series E Preferred Stock (taking into consideration the effect of the full adjustment of the anti-dilution provisions from such dilutive issuance) are permitted by General Instruction I.B.6. of Form S-3 to be issued under the registration statement; (iv) if we issue securities within the six months following the Series E Closing Date under the Series E Purchase Agreement, and subject to the preexisting rights of other security holders, the Series E Investors shall have the right of first refusal to purchase all of the securities on the same terms, conditions and price provided for in the proposed issuance of securities; and (v) we will indemnify the Series E Investors against certain losses resulting from the Company’s breach of any of its representations, warranties, or covenants under agreements with the Investors, as well as under certain other circumstances described in the Series E Purchase Agreement.
	The Series E Investors have agreed to be subject to a blocker that (i) would prevent each of their respective common stock ownership at any given time from exceeding 4.99% (which may be increased, but not above 9.99%) of our outstanding common stock; or (ii) would prevent us from issuing any shares of common stock to the Series E Investors upon the conversion of Series E Preferred Stock if the issuance of such shares, when aggregated with all other shares of common stock sold to the Series E Investors under the Series E Purchase Agreement together with all shares of common stock issued upon the conversion of Series E Preferred Stock, would result in the total issuance of common stock to exceed 19.99% of our outstanding common stock, without first obtaining the approval of our stockholders. We have agreed to seek stockholder approval at a special stockholders’ meeting to be held on April 28, 2015 for the terms of the Series E Preferred Stock and the issuance and delivery in the aggregate of that number of shares of common stock exceeding 19.99% of the outstanding shares of common stock upon conversion of the Series E Preferred Stock.
	The Series E Financing was effected as a takedown off the Company’s shelf registration statement on Form S-3 (File No. 333-198848), which became effective on September 19, 2014, pursuant to a prospectus supplement filed with the Securities and Exchange Commission on February 13, 2015.
	Private Placement Warrant Financing
	Substantially concurrently with the closing of the Series E Financing, on February 13, 2015, the Company entered into a separate securities purchase agreement (the “Warrant Purchase Agreement”) with selected accredited institutional pre-existing investors (the “Private Placement Investors”), pursuant to which we agreed to sell to the Private Placement Investors warrants to purchase 1,540,000 shares of Common Stock (the “Private Placement Warrants”, and the transactions contemplated by the Warrant Purchase Agreement, the “Warrant Financing”). In consideration of an aggregate of $1,000, we agreed to sell the Private Placement Warrants, which will not be issued unless and until our stockholders approve amending our Certificate of Incorporation to increase our authorized common stock in an amount sufficient to permit the issuance of the common stock issuable upon exercise of the Private Placement Warrants (the “Charter Amendment”).
	When issued, each Private Placement Warrant will have an exercise price of $2.167 per share of common stock (subject to adjustment for stock splits and the like), which represents 110% of the consolidated closing bid price of our common stock on Nasdaq immediately prior to entering into the Warrant Purchase Agreement, and will be exercisable at any time after the six month anniversary of entering into the Warrant Purchase Agreement and on or prior to the close of business on the five year anniversary of the initial exercise date, subject to the beneficial ownership limitation described below. The Private Placement Warrants are not subject to price based anti-dilution protection. If, at the time of exercise of a Private Placement Warrant, there is no effective registration statement registering for resale the shares of Common Stock issuable upon exercise of the Private Placement Warrant, the holder may exercise the Private Placement Warrant on a cashless basis. When exercised on a cashless basis, a portion of the Private Placement Warrant is cancelled in payment of the purchase price payable in respect of the number of shares of common stock purchasable upon such exercise. Subject to the beneficial ownership limitation described below, if, after the one year anniversary of the date of entering into the Warrant Purchase Agreement, the volume weighted average price of our common stock on Nasdaq exceeds 200% of the Private Placement Warrant exercise price for ten consecutive trading days, then we may, within one trading day thereafter, call for cancellation of up to 50% of the Private Placement Warrants for consideration equal to $0.001 per share of common stock underlying the Private Placement Warrants. We may not exercise our call rights if, among other things, there is no effective registration statement registering for resale the shares of common stock issuable upon exercise of the Private Placement Warrants. Subject to limited exceptions, a holder of Private Placement Warrants will not have the right to exercise any portion of its Private Placement Warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (which may be increased, but not above 9.99%) of the number of shares of our common stock outstanding immediately after giving effect to such exercise.
	For as long as the Private Placement Investors hold any Private Placement Warrants, we will not enter into an agreement to effect a “Variable Rate Transaction,” with similar terms and prohibitions described above. We also agreed that, except under certain permitted circumstances until the time that less than 7.5% of the Private Placement Warrants remain outstanding, neither the Company nor its subsidiaries shall issue, or enter into any agreement to issue, common stock or equivalents thereof at a price below the exercise price of the Private Placement Warrants. We also agreed that the terms of the Warrant Financing will be amended to the reflect the most favorable terms obtained by us in any future equity financing.
	We have agreed to seek stockholder approval at a special stockholders’ meeting to be held on April 28, 2015 for the Charter Amendment in connection with the Warrant Financing.
	Modification of Certain Outstanding Warrants
	In connection with the purchase of the Private Placement Warrants, we modified previously issued and outstanding warrants held by the Private Placement Investors that were issued in connection with the Series A, Series B and Series C financings described above, to (i) reduce the exercise prices thereunder to $1.97, which represents the consolidated closing bid price of our common stock on Nasdaq immediately prior to the date we entered into the Warrant Purchase Agreement; (ii) prohibit the exercise of such modified warrants for a period of six months after the date of the modification; and (iii) extend the exercise period of such modified warrants for an additional six months (such modifications, collectively, the “Warrant Price Modifications”). Separately, we also agreed to a Warrant Price Modification with a holder of Series C Warrants solely in consideration for such holder’s waiver of certain preemptive rights.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014							Dec. 31, 2013
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Accounting Principles and Fiscal Year End. The consolidated financial statements and accompanying notes are prepared on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles (“GAAP”). We have a December 31 year-end.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.
	Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including various state Medicaid programs, and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of state Medicaid contracts, published fee schedules for our tests. We report revenues from non-contracted payors based on the amounts expected to be collected. The differences between the amounts billed and the amounts expected to be collected from non-contracted payors are recorded as contractual allowances to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate, and also take into account recent collection trends. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the years ended December 31, 2014 and 2013, net positive revenue adjustments were $381,000 and $607,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. In all cases described above, we report revenues net of any applicable statutory taxes collected from customers, as applicable.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents and Short-Term Investments. We consider all highly liquid investments purchased with maturities of three months or less when purchased to be cash equivalents. Short-term investments consist of fixed income investments with maturities between three and 12 months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company’s consolidated balance sheets. Unrealized holding gains and losses are reported within comprehensive loss in the consolidated statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. If a decline in the fair value of a short-term investment below our cost basis is determined to be other than temporary, such investment is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, no permanent impairment charges have been realized or recorded.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	●     Level 1:     Observable market inputs such as quoted prices in active markets;
	●     Level 2:     Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly, such as quoted prices for similar assets or liabilities; and
	●     Level 3:     Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
	We classify our cash equivalents within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active markets for identical assets at the measurement date. We classify short-term investments within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these investments. Financial instruments that contain valuation inputs that are not readily determinable from active markets or from similar securities trading in active markets, such as derivative financial instruments, are classified within the fair value hierarchy as Level 3.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments. We evaluate financial instruments for freestanding or embedded derivatives. Derivative instruments that do not qualify for permanent equity classification are recorded as liabilities at fair value, with changes in value recognized as other income (expense) in the consolidated statements of operations in the period of change. Derivative liabilities are categorized as either short-term or long-term based upon management’s estimates as to when the derivative instrument may be realized or based upon the holder’s ability to realize the instrument.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risks. Cash and cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents. We do not believe that we are exposed to significant credit risk on cash and cash equivalents or on our short-term investments. Accounts receivable from one commercial insurance carrier of $318,000 exceeded 10% of our total accounts receivable balance as of December 31, 2014.
	Substantially all of the components and raw materials used in providing our testing services, including array slides and reagents, are currently provided to us from a limited number of sources or in some cases from a single source. Although we believe that alternative sources for those components and raw materials are available, any supply interruption in a sole-sourced component or raw material might result in up to a several-month production delay and materially harm our ability to provide testing services until a new source of supply, if any, could be located and qualified.
Receivables, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts. In the case of contracted third-party payors, governmental payors or direct-bill customers, accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for services performed. In the case of non-contracted customers, accounts receivable are stated at amounts expected to be collected based on historical collection experience with the third-party payor. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible after appropriate collection efforts have been exhausted. Such write-offs increase the contractual allowances for those accounts in the period of adjustment. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.
	Collection of receivables due from patients and private-pay clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. For these customers, an allowance for doubtful accounts is recorded for estimated uncollectible amounts, and involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables to assess our allowance at each period end. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.
Inventory Supplies, Policy [Policy Text Block]	Supplies. Supplies inventory, which consists primarily of raw materials to be used in the production of the arrays we use for our tests, is stated at the lower of cost or market using the first-in, first-out method.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment. Property and equipment is recorded at cost. Additions and improvements that increase the value or extend the life of an asset are capitalized. Maintenance and repairs are expensed as incurred. Disposals are removed at cost less accumulated depreciation or amortization and any gain or loss from disposition is reflected in the consolidated statements of operations in the period of disposition. Depreciation is computed on a straight-line basis over the following estimated useful lives of the assets:
	Laboratory equipment (in years)		3 to 5
	Furniture and fixtures (in years)		5 to 7
	Computer hardware and software (in years)		3
	Leasehold improvements		Lesser of lease term or useful life of improvement
	Certain leasehold improvements, furniture and equipment held under capital leases are classified as property and equipment and are amortized over their useful lives using the straight-line method. Lease amortization is included in depreciation expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation. The compensation cost for all employee stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally four years. The fair value of each stock option award is estimated on the date of grant using a Black-Scholes option valuation model. The fair value of each restricted stock unit (“RSU”) award is based on the number of shares granted and the closing price of our common stock on Nasdaq on the date of grant. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.
	The weighted average assumptions used to estimate the fair value of stock option awards granted for the periods presented are noted in the table below. Expected volatility is based on the separate historical volatility of the market prices of our common stock. The risk-free rate for the expected term, using the simplified method, of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
		For the Years Ended
		December 31,
		2014			2013
	Risk free interest rate		2.3	%		1.7	%
	Volatility		107.7	%		106	%
	Expected term (in years)	6.3			6.3
	Expected dividends		0	%		0	%
	Stock-based compensation expense for 2014 and 2013 attributable to our functional expense categories from stock option and RSU awards vesting during the periods presented was as follows (in thousands):
		For the Years Ended
		December 31,
		2014			2013
	Cost of services	$	17		$	7
	Sales and marketing		67			14
	General and administrative		444			411
	Total non-cash stock compensation	$	528		$	432
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses. Prior to launching a new test or modifying an existing test, extensive laboratory validations consistent with the various regulations that govern our industry must be performed.  As a result, research and development expenses include labor, laboratory supplies, and other development costs required to maintain and improve our existing suite of diagnostic test offerings as well as to investigate and develop new tests.  Costs to acquire technologies which are utilized in research and development and which have no alternative future use are expensed when incurred. Software developed for use in our services is expensed as incurred until both (i) technological feasibility for the software has been established and (ii) all research and development activities for the other components of the system have been completed. We believe these criteria are met after we have received evaluations from third-party test sites and completed any resulting modifications to the services. Expenditures to date have been classified as research and development expense.
Advertising Costs, Policy [Policy Text Block]	Advertising. Costs associated with marketing and advertising of our services are expensed as incurred. For the years ended December 31, 2014 and 2013, we incurred marketing and advertising expenses of $376,000 and $249,000, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes. We recognize income taxes on an accrual basis based on tax positions taken or expected to be taken in our tax returns. A tax position is defined as a position in a previously filed tax return or a position expected to be taken in a future tax filing that is reflected in measuring current or deferred income tax assets and liabilities. Tax positions are recognized only when it is more likely than not (i.e., likelihood of greater than 50%), based on technical merits, that the position would be sustained upon examination by taxing authorities. Tax positions that meet the more likely than not threshold are measured using a probability-weighted approach as the largest amount of tax benefit that is greater than 50% likely of being realized upon settlement. Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. A valuation allowance is established to reduce deferred tax assets if all, or some portion, of such assets will more than likely not be realized. Should they occur, our policy is to classify interest and penalties related to tax positions as income tax expense. Since our inception, no such interest or penalties have been incurred, however.
Comprehensive Income, Policy [Policy Text Block]								Other Comprehensive Loss. Components of comprehensive loss include unrealized gains and losses on available-for-sale securities and are included in the consolidated statements of comprehensive loss.
Segment Reporting, Policy [Policy Text Block]	Segments. We have determined that we operate in one segment for financial reporting purposes.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase CombiMatrix stock as well as preferred stock convertible into shares of common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table reflects the excluded dilutive securities:
		For the Years Ended
		December 31,
		2014			2013
	Common stock options		690,904			639,019
	Restricted stock units		302,725			-
	Common stock warrants		7,408,905			7,623,677
	Series D preferred stock convertible into common stock.		-			1,068,297
	Excluded potentially dilutive securities		8,402,534			9,330,993
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements. In November 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance on determining whether a host contract in a hybrid financial instrument issued in the form of a share is more akin to debt or to equity. This guidance does not change the current criteria in GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required, but instead clarifies how current GAAP should be interpreted in the evaluation of the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share, thereby reducing existing diversity in practice. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.
	In August 2014, the FASB issued new guidance requiring management of all entities to evaluate whether there are conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable). The guidance is effective for fiscal years beginning after December 15, 2016 and for interim periods within that fiscal year. We do not expect the adoption of this guidance to have a material effect on our consolidated financial statements.
	In May 2014, the FASB issued new accounting guidance regarding revenue recognition from contracts with customers, which when effective will supersede existing revenue recognition requirements and will eliminate most industry-specific guidance from generally accepted accounting principles. The core principle of the new guidance is to require an entity to recognize as revenue the amount that reflects the consideration to which it expects to be entitled in exchange for goods or services as it transfers control to its customers. The new guidance requires additional qualitative and quantitative disclosures about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. An entity can apply the new guidance retrospectively to each prior reporting period presented (i.e., the full retrospective method) or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new guidance becomes effective and will be adopted in the first quarter of fiscal year 2017 with early adoption not permitted. We are currently evaluating the appropriate transition method and any further impact of this guidance on our consolidated financial statements and related disclosures.
	In April 2014, the FASB amended guidance to clarify the accounting for disposals of groups of assets and business units. The amendments alter the definition of a discontinued operation to cover only asset disposals that are a strategic shift with a major effect on an entity's operations and finances. The changes should be applied in fiscal years that start on December 15, 2014, or later, but the changes can be applied ahead of the effective date for asset disposals that have not been reported in a set of financial statements. We do not believe adoption of this guidance will have a material impact on our consolidated financial statements or related disclosures.
	In July 2013, the FASB issued guidance on the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. Under this guidance, an unrecognized tax benefit, or a portion of an unrecognized tax benefit that exists at the reporting date, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if certain criteria are met. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2013 with early adoption permitted. The adoption of this guidance did not have a material impact on our consolidated financial statements or related disclosures.
	In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income or loss on the respective line items in net income or loss. The new accounting guidance does not change the items that must be reported in other comprehensive income or loss or when an item of other comprehensive income or loss must be reclassified to net income or loss. The guidance is effective prospectively for fiscal years beginning after December 15, 2012 and we were required to adopt these new provisions during the first quarter of 2013. As the guidance requires additional presentation only, there was no impact to our consolidated results of operations or financial position.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Note 2 - Summary of Significant Accounting Policies (Tables) [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		For the Years Ended
		December 31,
		2014			2013
	Risk free interest rate		2.3	%		1.7	%
	Volatility		107.7	%		106	%
	Expected term (in years)	6.3			6.3
	Expected dividends		0	%		0	%
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]		For the Years Ended
		December 31,
		2014			2013
	Cost of services	$	17		$	7
	Sales and marketing		67			14
	General and administrative		444			411
	Total non-cash stock compensation	$	528		$	432
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		For the Years Ended
		December 31,
		2014			2013
	Common stock options		690,904			639,019
	Restricted stock units		302,725			-
	Common stock warrants		7,408,905			7,623,677
	Series D preferred stock convertible into common stock.		-			1,068,297
	Excluded potentially dilutive securities		8,402,534			9,330,993
Useful Lives [Member]
Note 2 - Summary of Significant Accounting Policies (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]	Laboratory equipment (in years)		3 to 5
	Furniture and fixtures (in years)		5 to 7
	Computer hardware and software (in years)		3
	Leasehold improvements		Lesser of lease term or useful life of improvement

Note_3_Cash_and_Shortterm_Inve1

Note 3 - Cash and Short-term Investments (Tables)	12 Months Ended
	Dec. 31, 2014
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments [Table Text Block]		As of December 31, 2014									As of December 31, 2013
				Unrealized					Fair				Unrealized					Fair
		Cost		Gain		Loss			Value		Cost		Gain		Loss			Value
	Cash and money market securities	$	1,010	$	-	$	-		$	1,010	$	11,290	$	-	$	-		$	11,290
	Corporate bonds		1,003		-		-			1,003		-		-		-			-
	Certificates of deposit		3,230		-		(3	)		3,227		2,750		-		(4	)		2,746
		$	5,243	$	-	$	(3	)	$	5,240	$	14,040	$	-	$	(4	)	$	14,036
	Included in cash and cash equivalents.	$	1,010	$	-	$	-		$	1,010	$	12,290	$	-	$	(1	)	$	12,289
	Included in short-term investments		4,233		-		(3	)		4,230		1,750		-		(3	)		1,747
		$	5,243	$	-	$	(3	)	$	5,240	$	14,040	$	-	$	(4	)	$	14,036

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis [Table Text Block]					Fair Value Measurements
	31-Dec-14	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	676		$	676	$	-	$	-
	Short-term investments		4,230			-		4,230		-
	Total	$	4,906		$	676	$	4,230	$	-
					Fair Value Measurements
	31-Dec-13	Total			Level 1		Level 2		Level 3
	Assets:
	Cash equivalents	$	8,263		$	7,264	$	999	$	-
	Short-term investments		1,747			-		1,747		-
	Total	$	10,010		$	7,264	$	2,746	$	-
	Liabilities:
	Derivative warrant liability	$	568		$	-	$	-	$	568
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]		Derivative
		Warrant
		Liability
	Balance, December 31, 2013	$	568
	Changes in fair value		(152	)
	Reclassifications		(416	)
	Balance, December 31, 2014	$	-

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment (Tables) (Components [Member])	12 Months Ended
	Dec. 31, 2014
Components [Member]
Note 5 - Property and Equipment (Tables) [Line Items]
Property, Plant and Equipment [Table Text Block]		December 31,
		2014			2013
	Laboratory equipment	$	1,599		$	1,737
	Furniture and fixtures		290			225
	Computer hardware and software		38			42
	Leasehold improvements		252			279
			2,179			2,283
	Less - accumulated depreciation and amortization		(1,595	)		(1,702	)
		$	584		$	581

Note_6_Balance_Sheet_Component1

Note 6 - Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		December 31,
		2014		2013
	Accounts payable	$	381	$	636
	Payroll and other employee benefits		149		353
	Accrued vacation		207		144
	Royalties		252		211
	Other accrued expenses		118		23
		$	1,107	$	1,367

Note_7_Income_Taxes_Tables

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]		December 31,
		2014			2013
	Deferred tax assets:
	Deferred settlement costs	$	797		$	1,215
	Stock-based compensation		466			423
	Accrued liabilities and other		442			500
	Net operating loss carryforwards and credits		64,804			61,756
	Total deferred tax assets		66,509			63,894
	Less: valuation allowance		(66,514	)		(63,944	)
	Deferred tax assets, net of valuation allowance		(5	)		(50	)
	Deferred tax liabilities:
	Depreciation and amortization		5			50
	Net deferred tax liability	$	-		$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		December 31,
		2014			2013
	Statutory federal tax rate		(34%	)		(34%	)
	Impact on state tax rates		1	%		(7%	)
	Warrant valuation		(1%	)		(22%	)
	Cancellation of vested non-qualified stock options		0	%		1	%
	Valuation allowance		29	%		59	%
	Other non deductible permanent items		5	%		3	%
			0	%		0	%

Note_9_Commitments_and_Conting1

Note 9 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Years ending December 31:
		Operating		Capital
		Leases		Leases			Total
	2015	$	111	$	69		$	180
	2016		153		51			204
	2017		160		22			182
	2018		167		11			178
	2019 and thereafter		189		5			194
	Total minimum lease payments	$	780		158		$	938
	Less- imputed interest				(17	)
	Present value of capital lease obligations				141
	Less- current portion				(59	)
	Capital lease obligations, net of current portion..			$	82

Note_11_Stockholders_Equity_Ta

Note 11 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]		Shares of Common Stock
		Issuable from Warrants
		Outstanding as of December 31,				Exercise
		2014		2013		Price			Expiration
	Liability-classified warrants:
	Oct-12		-		292,817	$	2.06	(1)	Apr-18
			-		292,817
	Equity-classified warrants:
	Dec-13		5,825,243		5,825,243	$	3.12		Dec-18
	Jun-13		491,803		491,803	$	3.55		Dec-18
	May-13		491,803		491,803	$	3.77		Nov-18
	Mar-13		275,000		275,000	$	3.49		Sep-18
	Oct-12		194,009		-	$	2.06	(1)	Apr-18
	Apr-11		131,047		131,047	$	21.4		Apr-16
	Oct-09		-		3,000	$	77.8		Oct-14
	May-09		-		2,967	$	75.00 - $90.00		May 2014 - July 2014
	May-09		-		109,997	$	90		May-14
	Total		7,408,905		7,330,860
	Total - all warrants		7,408,905		7,623,677

Note_12_EquityBased_Compensati1

Note 12 - Equity-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Note 12 - Equity-Based Compensation (Tables) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]		December 31,
		2014			2013
	Weighted average fair values of options granted	$	2.4		$	2.39
	Options granted with exercise prices:
	Greater than market price on the grant date		-			-
	Equal to market price on the grant date		158,500			502,586
	Less than market price on the grant date		-			-
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]					Weighted
		Restricted			Average
		Stock			Grant Date
		Units			Fair Value
	Nonvested RSU's at December 31, 2013		-		$	-
	Granted		380,220		$	2.83
	Vested		-		$	-
	Cancelled		(77,495	)	$	2.81
	Nonvested RSU's at December 31, 2014		302,725		$	2.83
	Vested RSU's at December 31, 2014		-		$	-
CombiMatrix Plan [Member]
Note 12 - Equity-Based Compensation (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]							Weighted		Aggregate
					Weighted		Contractual		Intrinsic
					Average		Term		Value
		Shares			Price		(in years)		('000s)
	Balance at December 31, 2012		163,933		$	35.21		7.3	$	23
	Granted		502,586		$	3.29
	Exercised		-		$	-
	Forfeited		(13,750	)	$	9.68
	Cancelled		(13,750	)	$	28.94
	Balance at December 31, 2013		639,019		$	10.79		8.7	$	1
	Granted		158,500		$	2.87
	Exercised		-		$	-
	Forfeited		(103,555	)	$	3.89
	Cancelled		(6,105	)	$	31.09
	Balance at December 31, 2014		687,859		$	9.82		8	$	-
	Exercisable at December 31, 2013		98,259		$	47.75		6	$	-
	Exercisable at December 31, 2014		173,153		$	29.05		6.3	$	-
CMDX Plan [Member]
Note 12 - Equity-Based Compensation (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]							Weighted		Aggregate
					Weighted		Contractual		Intrinsic
					Average		Term		Value
		Shares			Price		(in years)		('000s)
	Balance at December 31, 2012		291,000		$	0.34		3.1	$	51
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		-		$	-
	Balance at December 31, 2013		291,000		$	0.34		2.1	$	51
	Granted		-		$	-
	Exercised		-		$	-
	Cancelled		-		$	-
	Balance at December 31, 2014		291,000		$	0.34		1.1	$	51
	Exercisable at December 31, 2013		241,000		$	0.3		2.1	$	50
	Exercisable at December 31, 2014		241,000		$	0.3		1.1	$	50

Note_1_Description_of_Business1

Note 1 - Description of Business (Details) (USD $)	0 Months Ended
	Feb. 13, 2015	Dec. 31, 2014	Dec. 31, 2013
Note 1 - Description of Business (Details) [Line Items]
Cash, Cash Equivalents, and Short-term Investments		$5,243,000	$14,040,000
Series E 6% Convertible Preferred Stock [Member] | Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 1 - Description of Business (Details) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock, Net	$4,700,000

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%
Net Revenue Adjustments	$381,000	$607,000
Marketing and Advertising Expense	376,000	249,000
From Commercial Insurance Carrier 1 [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Fair Value, Concentration of Risk, Accounts Receivable	$318,000
Restricted Stock Units (RSUs) [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Number of Reportable Segments	1
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Concentration Risk, Percentage	10.00%
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Equity Method Investment, Ownership Percentage	20.00%
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Equity Method Investment, Ownership Percentage	50.00%

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Property and Equipment - Estimated Useful Lives	12 Months Ended
	Dec. 31, 2014
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment Useful Life	3 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment Useful Life	5 years
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment Useful Life	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment Useful Life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant and Equipment Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements	Lesser of lease term or useful life of improvement

Note_2_Summary_of_Significant_4

Note 2 - Summary of Significant Accounting Policies (Details) - Share-based Compensation - Assumptions	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation - Assumptions [Abstract]
Risk free interest rate	2.30%	1.70%
Volatility	107.70%	106.00%
Expected term (in years)	6 years 109 days	6 years 109 days
Expected dividends	0.00%	0.00%

Note_2_Summary_of_Significant_5

Note 2 - Summary of Significant Accounting Policies (Details) - Stock-Based Compensation by Functional Expense Categories (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$528	$432
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	17	7
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	67	14
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation	$444	$411

Note_2_Summary_of_Significant_6

Note 2 - Summary of Significant Accounting Policies (Details) - Anti-Dilutive Securities	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	8,402,534	9,330,993
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	690,904	639,019
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	302,725
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	7,408,905	7,623,677
Series D Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities		1,068,297

Note_3_Cash_and_Shortterm_Inve2

Note 3 - Cash and Short-term Investments (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash and Cash Equivalents [Abstract]
Cash and Cash Equivalents, at Carrying Value	$1,010	$12,289
Short-term Investments	$4,230	$1,747

Note_3_Cash_and_Shortterm_Inve3

Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	$5,243	$14,040
Cash and Cash Equivalents, Unrealized Loss	-3	-4
Cash and Cash Equivalents, Fair Value	5,240	14,036
Included in cash and cash equivalents.	1,010	12,289
Included in cash and cash equivalents.		-1
Included in cash and cash equivalents.	1,010	12,289	2,372
Included in short-term investments	4,230	1,747
Included in short-term investments	-3	-3
Included in short-term investments	4,230	1,747
Cash and Money Market Securities [Member]
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	1,010	11,290
Cash and Cash Equivalents, Fair Value	1,010	11,290
Corporate Bonds [Member]
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	1,003
Cash and Cash Equivalents, Fair Value	1,003
Certificates of Deposit [Member]
Note 3 - Cash and Short-term Investments (Details) - Cash and Short-term Investments [Line Items]
Cash and Cash Equivalents, Cost	3,230	2,750
Cash and Cash Equivalents, Unrealized Loss	-3	-4
Cash and Cash Equivalents, Fair Value	$3,227	$2,746

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) - Financial Assets Measured on Recurring Basis (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets:
Cash equivalents	$676	$8,263
Short-term investments	4,230	1,747
Total	5,243	14,040
Liabilities:
Derivative warrant liability		568
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash equivalents	676	7,264
Total	676	7,264
Fair Value, Inputs, Level 2 [Member]
Assets:
Cash equivalents		999
Short-term investments	4,230	1,747
Total	4,230	2,746
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Derivative warrant liability		$568

Note_4_Fair_Value_Measurements3

Note 4 - Fair Value Measurements (Details) - Financial Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Financial Liabilities Measured at Fair Value on a Recurring Basis Using Level 3 Inputs [Abstract]
Balance	$568
Changes in fair value	-152
Reclassifications	-416	-1,111
Balance		$568

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization	$312,000	$352,000
Capital Leases, Balance Sheet, Assets by Major Class, Net	$159,000	$246,000

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment (Details) - Components of Property and Equipment (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment	$2,179	$2,283
Less - accumulated depreciation and amortization	-1,595	-1,702
	584	581
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,599	1,737
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	290	225
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	38	42
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$252	$279

Note_6_Balance_Sheet_Component2

Note 6 - Balance Sheet Components (Details) - Accounts Payable, Accrued Expenses and Other Accrued Expenses (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Payable, Accrued Expenses and Other Accrued Expenses [Abstract]
Accounts payable	$381	$636
Payroll and other employee benefits	149	353
Accrued vacation	207	144
Royalties	252	211
Other accrued expenses	118	23
	$1,107	$1,367

Note_7_Income_Taxes_Details

Note 7 - Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Gross	$66,509,000	$63,894,000
Operating Loss Carryforwards	169,000,000
Tax Credit Carryforward, Amount	$5,200,000

Note_7_Income_Taxes_Details_De

Note 7 - Income Taxes (Details) - Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred tax assets:
Deferred settlement costs	$797	$1,215
Stock-based compensation	466	423
Accrued liabilities and other	442	500
Net operating loss carryforwards and credits	64,804	61,756
Total deferred tax assets	66,509	63,894
Less: valuation allowance	-66,514	-63,944
Deferred tax assets, net of valuation allowance	-5	-50
Deferred tax liabilities:
Depreciation and amortization	5	50
Net deferred tax liability	$0	$0

Note_7_Income_Taxes_Details_Re

Note 7 - Income Taxes (Details) - Reconciliation of Income Tax Rate	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Income Tax Rate [Abstract]
Statutory federal tax rate	-34.00%	-34.00%
Impact on state tax rates	1.00%	-7.00%
Warrant valuation	-1.00%	-22.00%
Cancellation of vested non-qualified stock options	0.00%	1.00%
Valuation allowance	29.00%	59.00%
Other non deductible permanent items	5.00%	3.00%
	0.00%	0.00%

Note_8_Secured_Promissory_Note1

Note 8 - Secured Promissory Note (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	20-May-14
Note 8 - Secured Promissory Note (Details) [Line Items]
Secured Debt	$281,000
Secured Debt [Member]
Note 8 - Secured Promissory Note (Details) [Line Items]
Debt Instrument, Face Amount		350,000
Debt Instrument, Term	36 months
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Issuance Cost	22,000
Deferred Finance Costs, Net	18,000
Notes Payable	263,000
Notes Payable, Current	$112,000

Note_9_Commitments_and_Conting2

Note 9 - Commitments and Contingencies (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Oct. 24, 2014	Sep. 30, 2014
Note 9 - Commitments and Contingencies (Details) [Line Items]
Capital Leased Assets, Number of Units	11
Capital Leases, Original Purchase Amounts	$257,000
Capital Lease Obligations	158,000
Capital Lease Obligations, Weighted Average Interest Rate	8.20%
Operating Leases, Rent Expense	288,000	297,000
Litigation Settlement Percentage				12.50%
Maximum Annual Litigation Payment				1,500,000
Minimum Quarterly Litigation Payment				25,000
Royalty Expense	100,000	100,000
Laboratory Equipment [Member] | Maximum [Member]
Note 9 - Commitments and Contingencies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Laboratory Equipment [Member]
Note 9 - Commitments and Contingencies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] | The Amendment No. 6 [Member]
Note 9 - Commitments and Contingencies (Details) [Line Items]
Monthly Base Rent (in Dollars per Square Foot)			1.2
The Amendment No. 6 [Member] | Irvine, California [Member]
Note 9 - Commitments and Contingencies (Details) [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract			5 years
The Amendment No. 6 [Member]
Note 9 - Commitments and Contingencies (Details) [Line Items]
Tenant Improvements			0
Monthly Base Rent (in Dollars per Square Foot)			1
Increasing Monthly Base Rent, Thereafter (in Dollars per Square Foot)			0.05
Capital Leases of Lessee, Interest Rate	8.00%
Monthly Base Rent Estimated Common Area Expense (in Dollars per Square Foot)	0.85
Monthly Base Rent With Common Area Expense Future Minimum Payments Due, Next Twelve Months	22,500
Monthly Base Rent with Common Area Expense Future Minimum Payments Due in Five Years	$25,000

Note_9_Commitments_and_Conting3

Note 9 - Commitments and Contingencies (Details) - Future Minimum Lease Payments (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Future Minimum Lease Payments [Abstract]
2015	$111
2015	69
2015	180
2016	153
2016	51
2016	204
2017	160
2017	22
2017	182
2018	167
2018	11
2018	178
2019 and thereafter	189
2019 and thereafter	5
2019 and thereafter	194
Total minimum lease payments	780
Total minimum lease payments	158
Total minimum lease payments	938
Less- imputed interest	-17
Present value of capital lease obligations	141
Less- current portion	-59
Capital lease obligations, net of current portion..	$82	$65

Note_11_Stockholders_Equity_De

Note 11 - Stockholders' Equity (Details) (USD $)	1 Months Ended	12 Months Ended		3 Months Ended	6 Months Ended	0 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended	1 Months Ended	3 Months Ended
	Mar. 19, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2013	3-May-13	Jun. 28, 2013	Dec. 31, 2013	Dec. 31, 2013	Mar. 31, 2014	Dec. 20, 2013	Jun. 30, 2014	Jun. 30, 2014	Feb. 13, 2015	Sep. 30, 2014
Note 11 - Stockholders' Equity (Details) [Line Items]
Proceeds from Warrant Exercises (in Dollars)		$256,000	$3,142,000
Make Whole Payment, Per Share (in Dollars per share)		$118
Share Price (in Dollars per share)														$1,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)															$9.50
Warrants and Rights Outstanding (in Dollars)			568,000					568,000	568,000
Derivative, Gain on Derivative (in Dollars)		152,000	2,804,000
Warrant Liability Reclassified to Stockholders Equity (in Dollars)		416,000	1,111,000
Fair Value Adjustment of Warrants (in Dollars)		44,000
Interest Expense (in Dollars)		84,000	356,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	528,000
Series A Convertible Preferred Stock [Member] | Series A Warrants [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)				2,500,000
Series A Convertible Preferred Stock [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Conversion of Stock, Shares Converted					1,250,000
Preferred Stock, Dividend Rate, Percentage		6.00%
Stock Dividends, Shares			50,307
Dividends, Preferred Stock (in Dollars)			246,000
Series A Preferred Stock [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Preferred Stock, Stated Value (in Dollars per share)		$1,000
Series B Purchase Agreement [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	130,000
Series B Convertible Preferred Stock [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,610.40
Sale of Stock, Price Per Share (in Dollars per share)	3.05
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)	1,800,000
Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)	417,000
Series C Convertible Preferred Stock [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Conversion of Stock, Shares Converted								2,400
Share Price (in Dollars per share)						$1,000	$1,000
Stock Issued During Period, Shares, New Issues						1,200	1,200
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)			2,139,000				2,140,000
Debt Instrument, Convertible, Beneficial Conversion Feature (in Dollars)							1,200,000
Convertible Preferred Stock, Conversion Price (in Dollars per share)							$2.86
Convertible Preferred Stock, Shares Issued upon Conversion							839,864
Fair Value Inputs, Discount Rate							20.00%
Conversion of Stock, Shares Issued								839,864
Series D Convertible Preferred Stock [Member] | Net of Offering Costs [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)		10,700,000
Series D Convertible Preferred Stock [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Conversion of Stock, Shares Converted		9,799.30
Class of Warrant or Right, Number of Securities Called by Warrants or Rights											485.4369
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)											$3.12
Stock Issued During Period, Shares, New Issues											12,000
Sale of Stock, Price Per Share (in Dollars per share)			$1,000					1,000	$1,000
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)		-204,000	10,892,000
Convertible Preferred Stock, Shares Issued upon Conversion			5,825,243					5,825,243	5,825,243
Conversion of Stock, Shares Issued		4,756,946								1,068,297
Debt Instrument, Convertible, Conversion Price (in Dollars per share)											$2.06
Warrants, Term									5 years
Series A Warrants [Member] | Before Adjustment [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$2.86
Series A Warrants [Member] | Minimum [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Share Price (in Dollars per share)			$4.91					4.91	$4.91
Fair Value Assumptions, Expected Term		3 years 292 days	4 years 109 days
Fair Value Assumptions, Expected Volatility Rate			114.50%
Fair Value Assumptions, Risk Free Interest Rate			0.80%
Series A Warrants [Member] | Maximum [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Fair Value Assumptions, Expected Term			5 years
Fair Value Assumptions, Expected Volatility Rate			126.50%
Fair Value Assumptions, Risk Free Interest Rate			1.40%
Series A Warrants [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Stock Issued During Period, Shares, Warrant Exercised		124,111	1,200,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		25,303	292,817					292,817	292,817	81,910
Proceeds from Warrant Exercises (in Dollars)		256,000
Warrants Issued												25,303
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$2.06		$2.06	$2.06
Fair Value Assumptions, Expected Volatility Rate		129.60%
Fair Value Assumptions, Risk Free Interest Rate		1.20%
Warrants and Rights Outstanding (in Dollars)		281,000
Derivative, Gain on Derivative (in Dollars)		152,000	2,800,000										152,000
Warrant Liability Reclassified to Stockholders Equity (in Dollars)		416,000											281,000
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)			1,100,000
Series B Warrants [Member] | Fixed Combination [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	171
Share Price (in Dollars per share)	1,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	3.05
Series B Warrants [Member] | Maximum [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Warrant Agreement, Percentage of Warrants Outstanding Threshold	7.50%
Series B Warrants [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	275,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	3.49
Series C Warrant [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						491,803	491,803
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$3.77	$3.55
Warrant Agreement, Percentage of Warrants Outstanding Threshold							7.50%
Series D Warrant [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion			5,825,243					5,825,243	5,825,243
Net [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)									12,000,000
Amortization of Deferred Offering Costs [Member]
Note 11 - Stockholders' Equity (Details) [Line Items]
Interest Expense (in Dollars)			$280,000

Note_11_Stockholders_Equity_De1

Note 11 - Stockholders' Equity (Details) - Outstanding Warrants (USD $)	Dec. 31, 2014		Sep. 30, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	7,408,905			7,623,677
Exercise Price (in Dollars per share)			$9.50
Liability-classified Warrants [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding				292,817
October 2012 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	194,009			292,817
Exercise Price (in Dollars per share)	2.06	[1]
Equity-classified Warrants [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	7,408,905			7,330,860
December 2013 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	5,825,243			5,825,243
Exercise Price (in Dollars per share)	3.12
June 2013 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	491,803			491,803
Exercise Price (in Dollars per share)	3.55
May 2013 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	491,803			491,803
Exercise Price (in Dollars per share)	3.77
March 2013 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	275,000			275,000
Exercise Price (in Dollars per share)	3.49
April 2011 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding	131,047			131,047
Exercise Price (in Dollars per share)	21.4
October 2009 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding				3,000
Exercise Price (in Dollars per share)	77.8
May 2009 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	75
May 2009 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	90
May 2009 [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding				2,967
May 2009 II [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable From Warrants Outstanding				109,997
Exercise Price (in Dollars per share)	90
[1]	Prior to the anti-dilution adjustments which occurred on March 20, 2013, June 28, 2013 and December 20, 2013, these warrants had an initial exercise price of $9.50 per share. Also, due to the Modification previously discussed, these warrants are no longer liability classified as of September 30, 2014.

Note_12_EquityBased_Compensati2

Note 12 - Equity-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Note 12 - Equity-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)	$359,000	$279,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)	867,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 146 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	158,500	502,586
Restricted Stock Units (RSUs) [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 36 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options (in Dollars)	$672,000
Minimum [Member] | CombiMatrix Corporation 2006 Stock Incentive Plan [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Maximum [Member] | CombiMatrix Corporation 2006 Stock Incentive Plan [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Eligible Individuals [Member] | CombiMatrix Corporation 2006 Stock Incentive Plan [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Exercise Price Percent of Fair Market Value	100.00%
Eligible Employees [Member] | CombiMatrix Corporation 2006 Stock Incentive Plan [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Exercise Price Percent of Fair Market Value	100.00%
CombiMatrix Corporation 2006 Stock Incentive Plan [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	995,000
CMDX Plan [Member]
Note 12 - Equity-Based Compensation (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	3,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0

Note_12_EquityBased_Compensati3

Note 12 - Equity-Based Compensation (Details) - Stock Option Activities for CombiMatrix Plan (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Equity-Based Compensation (Details) - Stock Option Activities for CombiMatrix Plan [Line Items]
Granted	158,500	502,586
CombiMatrix Plan [Member]
Note 12 - Equity-Based Compensation (Details) - Stock Option Activities for CombiMatrix Plan [Line Items]
Balance at December 31	687,859	639,019	163,933
Balance at December 31	$9.82	$10.79	$35.21
Balance at December 31	8 years	8 years 255 days	7 years 109 days
Balance at December 31		$1	$23
Granted	158,500	502,586
Granted	$2.87	$3.29
Exercised		0
Exercised		$0
Forfeited	-103,555	-13,750
Forfeited	$3.89	$9.68
Cancelled	-6,105	-13,750
Cancelled	$31.09	$28.94
Exercisable at December 31	173,153	98,259
Exercisable at December 31	$29.05	$47.75
Exercisable at December 31	6 years 109 days	6 years

Note_12_EquityBased_Compensati4

Note 12 - Equity-Based Compensation (Details) - Options Granted (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Options Granted [Abstract]
Weighted average fair values of options granted	$2.40	$2.39
Options granted with exercise prices:
Equal to market price on the grant date	158,500	502,586

Note_12_EquityBased_Compensati5

Note 12 - Equity-Based Compensation (Details) - Restricted Stock Unit Activities (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock Units (RSUs) [Member]
Note 12 - Equity-Based Compensation (Details) - Restricted Stock Unit Activities [Line Items]
Nonvested RSU's	302,725	0
Nonvested RSU's	$2.83	$0
Granted	380,220
Granted	$2.83
Vested	0
Vested	$0
Cancelled	-77,495
Cancelled	$2.81

Note_12_EquityBased_Compensati6

Note 12 - Equity-Based Compensation (Details) - Stock Option Activities for CMDX Plan (USD $)	0 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Equity-Based Compensation (Details) - Stock Option Activities for CMDX Plan [Line Items]
Granted		158,500	502,586
CMDX Plan [Member]
Note 12 - Equity-Based Compensation (Details) - Stock Option Activities for CMDX Plan [Line Items]
Balance, shares	291,000	291,000	291,000	291,000
Balance, weighted average price	$0.34	$0.34	$0.34	$0.34
Balance, weighted contractual term	3 years 36 days	1 year 36 days	2 years 36 days
Balance, aggregate intrinsic value	$51	$51	$51	$51
Granted		0	0
Granted		$0	$0
Exercised		0	0
Exercised		$0	$0
Cancelled		0	0
Cancelled		$0	$0
Exercisable, shares		241,000	241,000
Exercisable, weighted average price		$0.30	$0.30
Exercisable, weighted contractual term		1 year 36 days	2 years 36 days
Exercisable, aggregate intrinsic value		$50	$50

Note_13_Subsequent_Events_Deta

Note 13 - Subsequent Events (Details) (USD $)	0 Months Ended
	Feb. 13, 2015	Sep. 30, 2014
Note 13 - Subsequent Events (Details) [Line Items]
Share Price (in Dollars per share)	$1,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$9.50
Private Placement Investors [Member] | Private Placement [Member] | Common Stock [Member] | Subsequent Event [Member] | Warrant Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	1,540,000
Series E 6% Convertible Preferred Stock [Member] | Common Stock [Member] | Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)	1,257,996
Series E 6% Convertible Preferred Stock [Member] | Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	2,201.49
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$1.97
Maximum Percentage of Convertible Stock into Outstanding Common Stock	19.99%
Proceeds from Issuance of Convertible Preferred Stock (in Dollars)	$4,900,000
Proceeds from Issuance of Convertible Preferred Stock, Net (in Dollars)	4,700,000
Preferred Stock, Dividend Rate, Percentage	6.00%
Percentage of Volume Weighted Average Price of Common Stock	200.00%
Conversion Price Consecutive Trading Days	10
Percentage of Preferred Stock OutstandingThreshold	7.50%
Private Placement [Member] | Subsequent Event [Member] | Modification of Certain Outstanding Warrants [Member] | Warrant Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$1.97
Private Placement [Member] | Subsequent Event [Member] | Warrant Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$2.17
Proceeds from Issuance of Warrants (in Dollars)	$1,000
Percentage of Closing Bid Price of Common Stock	110.00%
Percentage of Warrants Outstanding Threshold	7.50%
Series E Warrant [Member] | Common Stock [Member] | Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	317.965
Series E Warrant [Member] | Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Percentage of Warrants Cancelled Threshold	50.00%
Price Per Share of Common Stock (in Dollars per share)	$0.00
Common Stock [Member] | Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	700,000
Subsequent Event [Member] | Series E Purchase Agreement [Member]
Note 13 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	1,541,998
Share Price (in Dollars per share)	$1.75
Conversion Price (in Dollars per share)	$1.75
Maximum Common Stock Ownership by Investor	4.99%
Potential Maximum Common Stock Ownership by Investor	9.99%